Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

873 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Frequency and Significance of Body Weight Loss During Immunochemotherapy in Patients with Advanced Non-Small Cell Lung Cancer.
Taoka M, Ichihara E, Yokoyama T, Inoue K, Tamura T, Sato A, Oda N, Kano H, Nakamura K, Kawai H, Inoue M, Ochi N, Fujimoto N, Ichikawa H, Ando C, Oze I, Kiura K, Maeda Y, Hotta K. Taoka M, et al. Among authors: kano h. Cancers (Basel). 2024 Dec 6;16(23):4089. doi: 10.3390/cancers16234089. Cancers (Basel). 2024. PMID: 39682275 Free PMC article.
More than one-third of advanced non-small-cell lung cancer patients do not receive immunochemotherapy due to intolerance.
Ando C, Ichihara E, Yokoyama T, Inoue K, Tamura T, Fujiwara K, Oda N, Kano H, Kishino D, Watanabe K, Inoue M, Ochi N, Onishi F, Ichikawa H, Kobe H, Tachibana S, Hotta K, Maeda Y, Kiura K. Ando C, et al. Among authors: kano h. J Cancer Res Clin Oncol. 2023 Jul;149(8):4933-4938. doi: 10.1007/s00432-022-04415-1. Epub 2022 Oct 29. J Cancer Res Clin Oncol. 2023. PMID: 36308525
The Effect of Pleural Effusion on Prognosis in Patients with Non-Small Cell Lung Cancer Undergoing Immunochemotherapy: A Retrospective Observational Study.
Nishimura T, Ichihara E, Yokoyama T, Inoue K, Tamura T, Sato K, Oda N, Kano H, Kishino D, Kawai H, Inoue M, Ochi N, Fujimoto N, Ichikawa H, Ando C, Hotta K, Maeda Y, Kiura K. Nishimura T, et al. Among authors: kano h. Cancers (Basel). 2022 Dec 14;14(24):6184. doi: 10.3390/cancers14246184. Cancers (Basel). 2022. PMID: 36551668 Free PMC article.
Impacts of probiotics on the efficacies of immune checkpoint inhibitors with or without chemotherapy for patients with advanced non-small-cell lung cancer.
Morita A, Ichihara E, Inoue K, Fujiwara K, Yokoyama T, Harada D, Ando C, Kano H, Oda N, Tamura T, Ochi N, Kawai H, Inoue M, Hara N, Fujimoto N, Ichikawa H, Oze I, Hotta K, Maeda Y, Kiura K. Morita A, et al. Among authors: kano h. Int J Cancer. 2024 May 1;154(9):1607-1615. doi: 10.1002/ijc.34842. Epub 2024 Jan 9. Int J Cancer. 2024. PMID: 38196128
Randomized study comparing mannitol with furosemide for the prevention of cisplatin-induced renal toxicity in non-small cell lung cancer: The OLCSG1406 trial.
Makimoto G, Hotta K, Oze I, Ninomiya K, Nakanishi M, Hara N, Kano H, Watanabe H, Hata Y, Nishii K, Nakasuka T, Itano J, Ninomiya T, Kubo T, Ohashi K, Ichihara E, Minami D, Sato A, Tabata M, Maeda Y, Kiura K. Makimoto G, et al. Among authors: kano h. Asia Pac J Clin Oncol. 2021 Feb;17(1):101-108. doi: 10.1111/ajco.13423. Epub 2020 Sep 3. Asia Pac J Clin Oncol. 2021. PMID: 32885583 Clinical Trial.
VEGFR2 blockade augments the effects of tyrosine kinase inhibitors by inhibiting angiogenesis and oncogenic signaling in oncogene-driven non-small-cell lung cancers.
Watanabe H, Ichihara E, Kayatani H, Makimoto G, Ninomiya K, Nishii K, Higo H, Ando C, Okawa S, Nakasuka T, Kano H, Hara N, Hirabae A, Kato Y, Ninomiya T, Kubo T, Rai K, Ohashi K, Hotta K, Tabata M, Maeda Y, Kiura K. Watanabe H, et al. Among authors: kano h. Cancer Sci. 2021 May;112(5):1853-1864. doi: 10.1111/cas.14801. Epub 2021 Mar 18. Cancer Sci. 2021. PMID: 33410241 Free PMC article.
873 results